Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Summary

This phase II trial studies the side effects of azacitidine and pembrolizumab and to see how well they work in treating patients with myelodysplastic syndrome. Azacitidine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving azacitidine and pembrolizumab may work better at treating myelodysplastic syndrome.

Timeline

Start

2017-11-06

Primary completion

2021-11-06

Completion

2023-11-06

Drugs

Indications